Ghent, Belgium - 8 April 2022 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), an innovator in the treatment of diuretic-resistant fluid overload
Reporting of primary endpoint on track for Q4 2022FDA regulatory submission on track for mid-202370% survival of POSEIDON Roll-In patients at one year post-implantation1 compares favourably
Ghent, Belgium - 31 March 2022 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), an innovator in the treatment of diuretic-resistant fluid overload
PRESS RELEASEREGULATED INFORMATION 28 March 2022, 6 p.m. CET Ghent, Belgium - 28 March 2022 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical")